{"id":52035,"date":"2022-12-15T15:03:36","date_gmt":"2022-12-15T14:03:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/"},"modified":"2022-12-15T15:03:36","modified_gmt":"2022-12-15T14:03:36","slug":"propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/","title":{"rendered":"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n"},"content":{"rendered":"
\n

\nA Scientific Poster Describing a Novel Therapeutic Strategy Decreasing the Influence of the Tumor Microenvironment<\/i>\n<\/p>\n

MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc.<\/b><\/a> (OTC Pink: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company\u2019s Joint Researcher, Mrs. Bel\u00e9n Toledo Cutillas, MSc, at the laboratory of Professor Macarena Per\u00e1n, PhD, University of Ja\u00e9n, Spain, received an award for best poster at the \u201cDoctoral Days 2022 for Young Researchers of the University of Ja\u00e9n,\u201d conference. The poster, entitled, \u201cBlocking Tumor Support from Cancer Associated Fibroblasts in Tumor Microenvironment<\/i>,\u201d describes a novel therapeutic strategy to decrease tumor microenvironment (TME) influence in drug uptake, immune evasion, tumor progression and further tumor dispersion. A copy of the publication can be accessed from the Company\u2019s website, via the following link: https:\/\/www.propanc.com\/news-media\/publications<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nDespite cancer research budgets continuing to grow, and even with knowledge of the complex interaction between a tumor and its host organism, standard treatments are still inefficient, which continues to lead to extremely serious side effects and to the development of tumor relapses due to acquired chemoresistance. Cancer Associated Fibroblasts (CAFs), as the main cell population of the TME, play a key role in all stages of tumorigenesis, from tumor initiation to the induction of the pre-metastatic niche settlement; thus, it appears to seem evident that novel therapeutic approaches should hamper CAFs support to tumor cells.\n<\/p>\n

\n\u201cIn addition to the serious side effects from standard treatment, which we all acknowledge, the biggest question facing cancer sufferers is whether the cancer will return, post-treatment. This recurrence often results from acquired chemoresistance as a result of the influence toward the tumor microenvironment from CAFs,\u201d said Dr. Julian Kenyon, MD, MB, ChB, Propanc\u2019s Chief Scientific Officer and Cofounder. \u201cBel\u00e9n\u2019s pioneering work in this field demonstrates that Propanc\u2019s PRP can potentially impact chemoresistance from solid tumors by altering the TME, thus decreasing the risk of tumor recurrence, one of the biggest issues facing patients today. We continue to work closely with Bel\u00e9n and the team at the laboratory of Professor Per\u00e1n, as we progress to a First-In-Human study in advanced cancer patients and investigate possible new clinical applications for PRP in combination with standard treatment approaches.\u201d\n<\/p>\n

\nPRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.\n<\/p>\n

\nAbout Propanc Biopharma, Inc.<\/b>\n<\/p>\n

\nPropanc Biopharma, Inc. (the \u201cCompany\u201d) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com<\/a>.\n<\/p>\n

\nThe Company\u2019s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body\u2019s primary defense against cancer.\n<\/p>\n

\nTo view the Company\u2019s \u201cMechanism of Action\u201d video on its anti-cancer lead product candidate, PRP, please click on the following link: http:\/\/www.propanc.com\/news-media\/video<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nAll statements other than statements of historical facts contained in this press release are \u201cforward-looking statements,\u201d which may often, but not always, be identified by the use of such words as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cwill likely result,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201ccontinue,\u201d \u201ctarget,\u201d or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties, and other factors, that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company\u2019s ability to continue as a going concern absent new debt or equity financings; the Company\u2019s current reliance on substantial debt financing that, as of the date of this press release, it would have substantial difficulty repaying in cash; the Company\u2019s ability successfully to remediate material weaknesses in its internal controls; the Company\u2019s ability to reach research and development milestones as planned and within proposed budgets; the Company\u2019s ability to control costs; the Company\u2019s ability to obtain adequate new financing on reasonable terms on an as-needed basis; the Company\u2019s ability successfully to initiate and complete clinical trials and to develop PRP, its lead product candidate; the Company\u2019s ability to obtain and maintain patent protection; the Company\u2019s ability to recruit employees and directors with accounting and finance expertise; the Company\u2019s dependence on third parties for services; the Company\u2019s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions; competition; and other risks, including, but not limited to, those described in the Company\u2019s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http:\/\/www.sec.gov<\/a>. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations and Media:<\/b>
Mr. James Nathanielsz
\n
Propanc Biopharma, Inc.
\n
irteam@propanc.com<\/a>
+61-3-9882-0780\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

A Scientific Poster Describing a Novel Therapeutic Strategy Decreasing the Influence of the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company\u2019s Joint Researcher, Mrs. Bel\u00e9n Toledo Cutillas, MSc, at … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52035","6":"format-standard","7":"category-industry"},"yoast_head":"\nPropanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"A Scientific Poster Describing a Novel Therapeutic Strategy Decreasing the Influence of the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company\u2019s Joint Researcher, Mrs. Bel\u00e9n Toledo Cutillas, MSc, at ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-15T14:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221213005527\/en\/808594\/21\/propanc-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n\",\"datePublished\":\"2022-12-15T14:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/\"},\"wordCount\":914,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005527\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/\",\"name\":\"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005527\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\",\"datePublished\":\"2022-12-15T14:03:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005527\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005527\\\/en\\\/808594\\\/21\\\/propanc-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/","og_locale":"en_US","og_type":"article","og_title":"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n - Pharma Trend","og_description":"A Scientific Poster Describing a Novel Therapeutic Strategy Decreasing the Influence of the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company\u2019s Joint Researcher, Mrs. Bel\u00e9n Toledo Cutillas, MSc, at ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-15T14:03:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221213005527\/en\/808594\/21\/propanc-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n","datePublished":"2022-12-15T14:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/"},"wordCount":914,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005527\/en\/808594\/21\/propanc-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/","url":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/","name":"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005527\/en\/808594\/21\/propanc-logo.jpg","datePublished":"2022-12-15T14:03:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221213005527\/en\/808594\/21\/propanc-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221213005527\/en\/808594\/21\/propanc-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharmas-joint-researcher-receives-award-at-doctoral-conference-at-the-university-of-jaen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Propanc Biopharma\u2019s Joint Researcher Receives Award at Doctoral Conference at the University of Ja\u00e9n"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52035"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52035\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}